Release date: 2015-07-22
Scorpio gene ushered in the development opportunity period, in order to accelerate the pace of development, and reached strategic cooperation with Spectrum Run Investment, Shanlan Capital and Shengyu Investment, completed the first round of financing of RMB 80 million to enhance the scale and capacity of its business services and improve Industrial layout.
Tianyi Gene Technology (Suzhou) Co., Ltd. ("Tianyi Gene"), established in 2008, is located in the Bio-Nano Park of Suzhou Industrial Park. It is an innovative high-tech company mainly engaged in the development and application of genetic analysis technology. Science and technology biotechnology enterprises, the company currently has three wholly-owned subsidiaries: Shanghai Tianyi Biotechnology Co., Ltd. ("Tianyi Bio"), Tianzhu Biomedical Technology (Suzhou) Co., Ltd. ("Tianyi Diagnostics") and Scorpio Health Management Consulting (Shanghai) Co., Ltd. (referred to as "Tianyi Health"), the business content corresponds to scientific services and scientific research reagents, clinical molecular diagnostic reagents and medical tests, as well as popular genetic health screening and consultation.
Since its inception, Scorpio has been adhering to technological innovation as the core driving force for the company's sustainable development. It has developed a number of cost-effective multi-site genetic testing patent technologies, and developed several genetic testing kit products based on these technologies. Dr. Jiang Zhengwen, the general manager of the company, has won honors such as the national “Thousand Talents Program†entrepreneurial talent, Jiangsu “Double Talents†and Suzhou Industrial Park “Leading Talentsâ€. Subsidiary Tianyi Bio was also approved as a national high-tech enterprise.
The genetic testing industry has entered a period of rapid development in recent years, and its application needs in many fields such as maternal and child reproductive, genetic diseases, tumors, and infectious diseases are growing rapidly, becoming the fastest growing segment in the in vitro diagnostic (IVD) industry. . Recently, many excellent genetic testing companies have emerged abroad, such as Illumina, Affymetrix, Sequenom, Ariosa, Natera, etc. In contrast, most domestic companies lack the core technology of independent innovation, and it is difficult to launch differentiated competition. Scorpio gene has obvious advantages in technological innovation. Some multi-site genetic detection technologies have reached the international leading level. The developed kits have been highly recognized by the industry's authoritative doctors, and it has long attracted the attention of the capital market. In this round of financing, more than 10 investment companies have submitted cooperation intentions to Tianzhu Gene. After careful selection, Tianzhu Gene has reached a strategic cooperation with Spectrum Investment, Shanlan Capital and Shengyu Investment to complete the first round of financing of RMB 80 million. . The funds raised in this round will be mainly used for: (1) clinical trials and CFDA registration of five maternal and child reproductive related molecular diagnostic kits; (2) upgrade and expansion of Tianzhu Biotechnology Service Platform to enhance corresponding service capabilities and efficiency; (3) Construction and qualification application of medical laboratory; (4) Tianjian health marketing team formation and product promotion.
The use of this round of funds will help improve the internal management structure of Scorpio genes, increase the scale of the company's technology services, accelerate the registration of the company's core molecular diagnostic products and bring them to market as soon as possible, and promote the development of new health products in Tianzhu, thus completing the technology services. With the research reagents, molecular diagnostic reagents and medical tests, as well as the public genetic health screening and consulting three industrial layouts.
This round of financing will provide a solid foundation for Scorpio genes to achieve greater corporate value and social value. The company will uphold the corporate tenet of "innovative genetic technology, protect human health", undertake corporate mission, and give back to society with better service. We continue to make positive contributions to the molecular diagnostics industry, and strive to make Scorpio genes an innovative representative in the field of domestic genetic testing, and products affect international brands in the world.
Source: Bio Valley
Substitute tea refers to the use of edible plant leaves, flowers, fruits (fruit), roots, etc., using the way of drinking tea (by brewing, boiling, etc.) is a kind of products commonly known.
Substitute tea is divided into leaf, flower, fruit and rhizome; The way of drinking the same as tea is generally composed of one or more items in the two categories of "medicine and food homology" and "can be used for health care" in the food classification stipulated by the Ministry of Health. Tea products made from the roots, stems, leaves or fruits of these plants.
The way of drinking the same as tea, generally by the ministry of Health provisions of food classification of medicine and food homologous category, can be used for health care category, two types of goods in the single or multiple items, with the roots, stems, leaves or fruits of these plants made of tea products.
Substitute tea has certain effect and auxiliary effect for some special groups, belonging to the health conditioning products.
Alternative Tea,Hot Drink Alternative To Tea,Tea Substitute,Green Tea Alternative
XuChang Youjia Food Product Development Co., LTD , https://www.yjgrain.com